New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
Authors
Keywords
Renal cell carcinoma, Sorafenib resistance, Molecular mechanisms, Biomarkers, Precision therapy
Journal
PHARMACOLOGICAL RESEARCH
Volume 170, Issue -, Pages 105732
Publisher
Elsevier BV
Online
2021-06-16
DOI
10.1016/j.phrs.2021.105732
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma
- (2020) YOHEI SEKINO et al. ANTICANCER RESEARCH
- Long Noncoding RNA KIF9-AS1 Regulates Transforming Growth Factor-β and Autophagy Signaling to Enhance Renal Cell Carcinoma Chemoresistance via microRNA-497-5p
- (2020) Yichen Jin et al. DNA AND CELL BIOLOGY
- Molecular targeting of renal cell carcinoma by an oral combination
- (2020) Andre R. Jordan et al. Oncogenesis
- Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial
- (2020) Jianhui Ma et al. Frontiers in Oncology
- New insights on sorafenib resistance in liver cancer with correlation of individualized therapy
- (2020) Zhang Cheng et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Genomic profiling in renal cell carcinoma
- (2020) Nazli Dizman et al. Nature Reviews Nephrology
- Targeting the HIF2–VEGF axis in renal cell carcinoma
- (2020) Toni K. Choueiri et al. NATURE MEDICINE
- Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
- (2019) Xiang Chen et al. Targeted Oncology
- Extracellular vesicles transmitted miR‐31‐5p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma
- (2019) Jinlan He et al. INTERNATIONAL JOURNAL OF CANCER
- Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
- (2019) Huan Deng et al. Frontiers in Oncology
- Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma
- (2019) Xiaoge Gao et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
- (2019) David J. Clark et al. CELL
- Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer
- (2019) Carmine D'Aniello et al. Frontiers in Oncology
- Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response
- (2018) Yi Bao et al. BRITISH JOURNAL OF CANCER
- RASSF6-mediated inhibition of Mcl-1 through JNK activation improves the anti-tumor effects of sorafenib in renal cell carcinoma
- (2018) Ying-Ying Liang et al. CANCER LETTERS
- Long non-coding RNA GAS5 sensitizes renal cell carcinoma to sorafenib via miR-21/SOX5 pathway
- (2018) Lei Liu et al. CELL CYCLE
- Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells
- (2018) Xinyi Yu et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer
- (2018) Yang Ge et al. INTERNATIONAL JOURNAL OF CANCER
- phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer
- (2018) Cun Wang et al. JOURNAL OF HEPATOLOGY
- Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
- (2018) Daniel J. Crona et al. CANCER RESEARCH
- SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)
- (2018) Margitta Retz et al. EUROPEAN JOURNAL OF CANCER
- Sorafenib: key lessons from over 10 years of experience
- (2018) Bernard Escudier et al. Expert Review of Anticancer Therapy
- Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer
- (2018) Kyung Hwa Choi et al. Translational Oncology
- Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents
- (2017) Giovanni Luca Beretta et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance
- (2017) Yonghua Sheng et al. INTERNATIONAL JOURNAL OF CANCER
- Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma
- (2017) Wei Xiao et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The significance of TIMD4 expression in clear cell renal cell carcinoma
- (2017) Hiromu Yano et al. Medical Molecular Morphology
- Systemic Therapy for Metastatic Renal-Cell Carcinoma
- (2017) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti‐Angiogenic Therapy and Exploratory Predictive Biomarker Analysis
- (2017) James Xunhai Xu et al. ONCOLOGIST
- Korean Red Ginseng Extract Enhances the Anticancer Effects of Sorafenib through Abrogation of CREB and c-Jun Activation in Renal Cell Carcinoma
- (2017) Chulwon Kim et al. PHYTOTHERAPY RESEARCH
- miR-195-5p is critical in REGγ-mediated regulation of wnt/β-catenin pathway in renal cell carcinoma
- (2017) Shaojun Chen et al. Oncotarget
- The long non-coding RNA NEAT1 enhances epithelial-to-mesenchymal transition and chemoresistance via the miR-34a/c-Met axis in renal cell carcinoma
- (2017) Fei Liu et al. Oncotarget
- The coffee diterpene kahweol enhances sensitivity to sorafenib in human renal carcinoma Caki cells through down-regulation of Mcl-1 and c-FLIP expression
- (2017) Kyoung-Jin Min et al. Oncotarget
- Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
- (2017) Tingyu Wen et al. Oncotarget
- Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade
- (2017) Kei Ishibashi et al. Oncotarget
- Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells
- (2017) Zofia F. Bielecka et al. Cell and Bioscience
- Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib
- (2016) Tetsuo Fujita et al. ANTI-CANCER DRUGS
- Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice
- (2016) Andrea N. Edginton et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tyrosine receptor kinase B silencing inhibits anoikis-resistance and improves anticancer efficiency of sorafenib in human renal cancer cells
- (2016) PENG ZHANG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma
- (2016) Z Xu et al. ONCOGENE
- Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism
- (2016) Shuai Liu et al. Oncotarget
- The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma
- (2016) Chao Qin et al. Scientific Reports
- MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib
- (2015) Bing Zheng et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma
- (2015) Thai H Ho et al. BMC CANCER
- Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan
- (2015) Masatoshi Eto et al. BMC CANCER
- HIF2α is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma
- (2015) Carla Micucci et al. BRITISH JOURNAL OF CANCER
- Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma
- (2015) Bernard Escudier et al. Clinical Genitourinary Cancer
- Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity
- (2015) Brian Shuch et al. EUROPEAN UROLOGY
- BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma—A Trial of the ECOG–ACRIN Cancer Research Group (E2804)
- (2015) Keith T. Flaherty et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
- (2015) V. L. Bridgeman et al. MOLECULAR CANCER THERAPEUTICS
- Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo
- (2015) Hiromoto Tei et al. Human Cell
- Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy
- (2015) Terence C. Tang et al. NEOPLASIA
- Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
- (2014) Saadia A Aziz et al. Cancer Cell International
- Stem Cells Increase in Numbers in Perinecrotic Areas in Human Renal Cancer
- (2014) M. Varna et al. CLINICAL CANCER RESEARCH
- Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
- (2014) B. Escudier et al. CLINICAL CANCER RESEARCH
- Tyrosine Kinase Inhibitor Sorafenib Decreases 111In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma
- (2014) C. H. J. Muselaers et al. JOURNAL OF NUCLEAR MEDICINE
- Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2
- (2014) Chun-Xiong Zhao et al. MEDICAL ONCOLOGY
- Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma
- (2014) B. Zhai et al. MOLECULAR CANCER THERAPEUTICS
- Landmarks in the diagnosis and treatment of renal cell carcinoma
- (2014) Jaimin R. Bhatt et al. Nature Reviews Urology
- Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
- (2014) Shailender Bhatia et al. Journal for ImmunoTherapy of Cancer
- Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial
- (2013) G. Procopio et al. ANNALS OF ONCOLOGY
- Effects of hypoxia on human cancer cell line chemosensitivity
- (2013) Sara Strese et al. BMC CANCER
- Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC)
- (2013) J. P. Maroto et al. Clinical & Translational Oncology
- Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model
- (2013) K. Harada et al. Clinical & Translational Oncology
- GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC)
- (2012) Hisashi Kawazoe et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model
- (2012) Y Kususda et al. BRITISH JOURNAL OF CANCER
- AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney
- (2012) Brian Rini et al. CANCER
- Could Interferon Still Play a Role in Metastatic Renal Cell Carcinoma? A Randomized Study of Two Schedules of Sorafenib Plus Interferon-Alpha 2a (RAPSODY)
- (2012) Sergio Bracarda et al. EUROPEAN UROLOGY
- Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma
- (2012) JOHN SHYI PENG YUEN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Dietary Supplement Hymecromone and Sorafenib: A Novel Combination for the Control of Renal Cell Carcinoma
- (2012) Anaid Benitez et al. JOURNAL OF UROLOGY
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
- (2012) Wanjuan Yang et al. NUCLEIC ACIDS RESEARCH
- A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma
- (2011) A. J. Zurita et al. ANNALS OF ONCOLOGY
- Multidrug Resistance Protein 2 Implicates Anticancer Drug-Resistance to Sorafenib
- (2011) Yoshihiko Shibayama et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases
- (2011) Camillo Porta et al. BJU INTERNATIONAL
- A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma
- (2011) Andrea L. Harzstark et al. CANCER
- Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
- (2011) G. J. Weiss et al. CLINICAL CANCER RESEARCH
- Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
- (2011) Didier Roulin et al. Molecular Cancer
- Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma
- (2011) Rit Vatsyayan et al. MOLECULAR CARCINOGENESIS
- Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression
- (2011) Liang Zhang et al. PLoS One
- Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma
- (2010) Keith T. Flaherty et al. CANCER BIOLOGY & THERAPY
- Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2010) C. Pena et al. CLINICAL CANCER RESEARCH
- Does Arterial Spin-labeling MR Imaging–measured Tumor Perfusion Correlate with Renal Cell Cancer Response to Antiangiogenic Therapy in a Mouse Model?
- (2009) Rachel Schor-Bardach et al. RADIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now